|Last Price$5.60||Day Change (%)3.51%|
|Open Price$5.47||Day Change ($)0.19|
|Day Range5.38–5.75||52-Week Range1.26–6.38|
As of Wed 7/29/2015 5:14:00 PM | USD
Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
We see opportunity as fleeing investors trigger an irrational sell-off.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.